Cogent Biosciences Inc (COGT) Stock Price, Quote & News

Company Profile

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The c...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 945 5576

Website: www.cogentbio.com

Address:

275 Wyman Street, 3rd Floor, Waltham, United States

Albino_Trader123 Feb. 19 at 6:45 AM

$COGT Setting up nicely.

0 · Reply

Albino_Trader123 Feb. 19 at 6:44 AM

$JAZZ Tech market still very choppy. But some bio names are setting up really nice. $REGN $JAZZ $COGT JAZZ super pipeline and massive beat on last ER

0 · Reply

Dr_Stoxx Feb. 18 at 4:11 PM

$COGT: sooner or later..."the longer the base, the bigger..." as they say.

0 · Reply

erevnon Feb. 18 at 1:11 PM

Piper Sandler maintains Cogent Biosciences $COGT at Overweight and raises the price target from $39 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

DonCorleone77 Feb. 18 at 11:47 AM

$COGT Cogent Biosciences price target raised to $52 from $39 at Piper Sandler Piper Sandler raised the firm's price target on Cogent Biosciences to $52 from $39 and keeps an Overweight rating on the shares following Q4 reporting as the company shifts its primary focus to regulatory approvals and commercial readiness. With a hat trick of positive pivotal data for bezuclastinib in 2025, the narrative turns to execution, says the firm. The NonAdvSM NDA has been submitted with acceptance expected this month, positioning the drug for potential approval and launch in the second half of 2026. Piper continues to recommend Cogent shares as the company de-risks its regulatory path and transitions to a commercial entity.

0 · Reply

StocktwitsEarnings Feb. 17 at 5:00 PM

$COGT Q4 '25 Earnings Results & Recap Cogent Biosciences expects to launch bezuclastinib commercially in the United States in the second half of 2026 for NonAdvSM and second-line GIST patients, pending regulatory approval.

0 · Reply

d_risk Feb. 17 at 3:52 PM

$COGT - Cogent Biosciences Inc - 10K - Updated Risk Factors COGT’s 2026 10-K sharpens risk around bezuclastinib’s path to market: tougher competition, fragile trial data and companion diagnostics, heightened global regulatory and reimbursement pressure (including new U.S. pricing and “One Big Beautiful Bill” constraints), heavier reliance on third parties and single-source supply, expanded IP and cybersecurity exposures, concentrated insider control, stock/notes-related capital structure risks, and execution risk on a first commercial launch. #Biotechnology #Pharmaceuticals #RegulatoryRisk #MarketCompetition #IPAndCybersecurity 🟢 Added 🟠 Removed https://d-risk.ai/COGT/10-K/2026-02-17

0 · Reply

DonCorleone77 Feb. 17 at 1:13 PM

$COGT Cogent Biosciences sees cash runway into 2028 As of December 31, 2025, Cogent had cash, cash equivalents and marketable securities of $900.8 million. Fourth quarter cash usage was driven largely by non-recurring items, including the repayment of $54.8 million of long-term debt and approximately $38.5 million of one-time, performance-based equity compensation.

0 · Reply

DonCorleone77 Feb. 17 at 1:13 PM

$COGT Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year "Following three positive pivotal trials in 2025, we have entered 2026 with tremendous momentum and multiple value-creating regulatory catalysts underway," said Andrew Robbins, Cogent's President and Chief Executive Officer. "We have submitted our SUMMIT NDA for bezuclastinib in patients with NonAdvSM, initiated our PEAK NDA under the FDA's RTOR program for bezuclastinib in patients with second-line GIST, and remain on track to submit our APEX NDA for bezuclastinib in patients with AdvSM in the first half of this year. These recent and upcoming milestones underscore the breadth of bezuclastinib's best-in-class potential across KIT-mutant driven diseases. With a very strong balance sheet entering 2026, we will soon finish building our commercial organization and will be ready to launch bezuclastinib in the second half of 2026."

0 · Reply

Dr_Stoxx Feb. 11 at 4:07 PM

$COGT price action just contines to baffle. Look at that 50sma holding the line on the pops. Not for long...but it really tries the patience.

1 · Reply

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Feb 10, 2026, 8:00 AM EST - 9 days ago

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

Jan 26, 2026, 8:00 AM EST - 24 days ago

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

Jan 22, 2026, 10:26 AM EST - 27 days ago

These 20 stocks are strong choices for momentum investors

BE CELC FBYD FRGE INBX KOD LITE

Jan 20, 2026, 8:00 AM EST - 4 weeks ago

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

Jan 13, 2026, 5:15 PM EST - 5 weeks ago

Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:00 AM EST - 5 weeks ago

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

Jan 6, 2026, 8:00 AM EST - 6 weeks ago

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Jan 2, 2026, 11:44 AM EST - 6 weeks ago

Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day.

Dec 30, 2025, 8:00 AM EST - 7 weeks ago

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis

Dec 8, 2025, 4:27 PM EST - 2 months ago

Cogent Biosciences, Inc. (COGT) Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference Transcript

Dec 6, 2025, 9:30 AM EST - 2 months ago

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

Dec 3, 2025, 6:22 PM EST - 2 months ago

3 Potential Mid-Cap Biotech Buyout Targets In 2026

IBB TVTX XBI CYTK

Nov 14, 2025, 8:00 AM EST - 3 months ago

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

Nov 11, 2025, 11:16 PM EST - 3 months ago

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031

Nov 11, 2025, 10:34 AM EST - 3 months ago

Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside

Nov 10, 2025, 4:01 PM EST - 3 months ago

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Nov 10, 2025, 2:27 PM EST - 3 months ago

Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy

Nov 10, 2025, 1:41 PM EST - 3 months ago

Cogent Biosciences, Inc. (COGT) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors Transcript

Nov 10, 2025, 10:28 AM EST - 3 months ago

Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial

Nov 10, 2025, 7:00 AM EST - 3 months ago

Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)

Nov 3, 2025, 9:01 AM EST - 3 months ago

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 3, 2025, 9:00 AM EST - 3 months ago

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

Oct 24, 2025, 12:30 PM EDT - 4 months ago

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 20, 2025, 8:32 AM EDT - 4 months ago

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib

Sep 29, 2025, 4:05 PM EDT - 5 months ago

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 3, 2025, 3:07 PM EDT - 6 months ago

Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 26, 2025, 8:00 AM EDT - 6 months ago

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

Aug 5, 2025, 8:00 AM EDT - 7 months ago

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 10, 2025, 4:01 PM EDT - 7 months ago

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 9, 2025, 4:04 PM EDT - 8 months ago

Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results

Jul 8, 2025, 9:36 PM EDT - 8 months ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Jul 8, 2025, 4:26 PM EDT - 8 months ago

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

Jul 7, 2025, 9:22 AM EDT - 8 months ago

Why Is Cogent Biosciences Stock Trading Higher On Monday?

Jul 7, 2025, 7:06 AM EDT - 8 months ago

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

Jun 11, 2025, 8:00 AM EDT - 9 months ago

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing

May 6, 2025, 8:00 AM EDT - 10 months ago

Cogent Biosciences Reports First Quarter 2025 Financial Results

Apr 25, 2025, 8:08 AM EDT - 10 months ago

Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

Mar 25, 2025, 4:31 PM EDT - 11 months ago

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 7, 2025, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Feb 25, 2025, 8:00 AM EST - 1 year ago

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Feb 10, 2025, 9:15 AM EST - 1 year ago

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

Jan 22, 2025, 12:29 PM EST - 1 year ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN JAZZ ONC XBI ZYME

Jan 18, 2025, 3:27 AM EST - 1 year ago

Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data

Dec 9, 2024, 7:00 AM EST - 1 year ago

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Dec 8, 2024, 12:00 PM EST - 1 year ago

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Jun 14, 2024, 7:30 AM EDT - 1 year ago

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

May 23, 2024, 5:05 PM EDT - 1 year ago

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

May 23, 2024, 5:01 PM EDT - 1 year ago

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

Albino_Trader123 Feb. 19 at 6:45 AM

$COGT Setting up nicely.

0 · Reply

Albino_Trader123 Feb. 19 at 6:44 AM

$JAZZ Tech market still very choppy. But some bio names are setting up really nice. $REGN $JAZZ $COGT JAZZ super pipeline and massive beat on last ER

0 · Reply

Dr_Stoxx Feb. 18 at 4:11 PM

$COGT: sooner or later..."the longer the base, the bigger..." as they say.

0 · Reply

erevnon Feb. 18 at 1:11 PM

Piper Sandler maintains Cogent Biosciences $COGT at Overweight and raises the price target from $39 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

DonCorleone77 Feb. 18 at 11:47 AM

0 · Reply

StocktwitsEarnings Feb. 17 at 5:00 PM

0 · Reply

d_risk Feb. 17 at 3:52 PM

0 · Reply

DonCorleone77 Feb. 17 at 1:13 PM

0 · Reply

DonCorleone77 Feb. 17 at 1:13 PM

0 · Reply

Dr_Stoxx Feb. 11 at 4:07 PM

$COGT price action just contines to baffle. Look at that 50sma holding the line on the pops. Not for long...but it really tries the patience.

1 · Reply

SuperGreenToday Feb. 11 at 12:21 PM

$COGT Share Price: $37.80 Contract Selected: May 15, 2026 $40 Calls Buy Zone: $4.44 – $5.48 Target Zone: $7.74 – $9.46 Potential Upside: 65% ROI Time to Expiration: 92 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Dr_Stoxx Feb. 9 at 4:11 PM

$COGT looks good, finally. Some of you may still be with me in this one...just a "mention" trade a couple weeks ago but has not done much since then.

1 · Reply

OfficialStocktwitsUser Feb. 3 at 3:58 AM

$COGT RSI: 60.35, MACD: 0.2859 Vol: 1.85, MA20: 37.23, MA50: 38.13 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday Feb. 2 at 12:14 PM

$COGT Share Price: $35.91 Contract Selected: May 15, 2026 $35 Calls Buy Zone: $5.18 – $6.41 Target Zone: $8.93 – $10.92 Potential Upside: 63% ROI Time to Expiration: 101 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SuperGreenToday Jan. 30 at 11:51 AM

$COGT Share Price: $37.66 Contract Selected: May 15, 2026 $40 Calls Buy Zone: $4.44 – $5.48 Target Zone: $8.15 – $9.96 Potential Upside: 73% ROI Time to Expiration: 104 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Jimmyboy29 Jan. 26 at 7:12 PM

$COGT i want to buy shares and options on this but i just dont understand why insiders sold 3m shares recently..🧐

1 · Reply

DARKP00L Jan. 26 at 1:09 PM

$COGT 08:03 on Jan. 26 2026 The FDA Grants Breakthrough Therapy Designation To Cogent Biosciences' Bezuclastinib Plus Sunitinib For Gastrointestinal Stromal Tumor Patients Previously Treated With Imatinib #tradeideas

0 · Reply

HahaYouSUCK Jan. 21 at 2:04 PM

$COGT this will get BO next year. Better than BPMC

0 · Reply

CH_Expat Jan. 20 at 4:16 PM

$COGT Still biggest all-time-miss.

1 · Reply

ZapCricket Jan. 20 at 3:41 PM

$COGT microcap biotech thin tape low attention if ca

0 · Reply

DARKP00L Jan. 20 at 1:14 PM

$COGT 08:10 on Jan. 20 2026 Cogent Biosciences To Initiate New Drug Application Submission For Bezuclastinib Under Real-Time Oncology Review #tradeideas

0 · Reply

SuperGreenToday Jan. 20 at 1:09 PM

$COGT Share Price: $38.91 Contract Selected: May 15, 2026 $40 Calls Buy Zone: $5.81 – $7.18 Target Zone: $10.53 – $12.87 Potential Upside: 71% ROI Time to Expiration: 114 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	5.36B
Revenue (ttm)	0.00
Net Income (ttm)	-255.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	2,778,200
Avg Vol	2,251,790
Day's Range	N/A - N/A
Shares Out	142.38M
Stochastic %K	66%
Beta	0.45
Analysts	Strong Sell
Price Target	$52.58